GlassScriptPhysician profile
Stacey Wells
NPI 1538554993
$3,641.58
in general payments reported to CMS, 2019-2025
51 companies · $831 in 2025
The $831 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $188 · 2021: $586 · 2022: $689 · 2023: $616 · 2024: $731 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.87 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $397.14 | 2022-2025 | |
| Pfizer INC. | $291.45 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $289.37 | 2021-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $269.77 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $233.02 | 2020-2025 | Monjuvi, Pemazyre, Jakafi |
| Emd Serono, INC. | $184.96 | 2020-2023 | Bavencio |
| Abbvie INC. | $174.57 | 2021-2025 | |
| Janssen Biotech, INC. | $154.20 | 2020-2025 | Erleada, Rybrevant, Balversa |
| Daiichi Sankyo INC. | $125.32 | 2020-2025 | Enhertu |
| Amgen INC. | $114.18 | 2020-2023 | Vectibix, Nplate, Xgeva |
| Eisai INC. | $99.45 | 2021-2025 | |
| Myovant Sciences INC. | $97.61 | 2021-2022 | |
| Astellas Pharma US INC | $89.64 | 2021-2023 | Xtandi |
| Ipsen Biopharmaceuticals, INC | $79.83 | 2020-2024 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $77.28 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.